| Literature DB >> 15295704 |
John P DeVincenzo1, Caroline B Hall, David W Kimberlin, Pablo J Sánchez, William J Rodriguez, Barbara A Jantausch, Lawrence Corey, Jeffrey S Kahn, Janet A Englund, JoAnn A Suzich, Frances J Palmer-Hill, Luis Branco, Syd Johnson, Nita K Patel, Franco M Piazza.
Abstract
Premature infants and those with chronic lung disease or congenital heart disease are at high risk of severe respiratory syncytial virus (RSV) disease. Palivizumab (Synagis), a humanized anti-RSV monoclonal antibody, has been used extensively since 1998 to prevent severe RSV disease in high-risk infants. To monitor for possible palivizumab-resistant mutants, an immunofluorescence binding assay that predicts palivizumab neutralization of RSV was developed. RSV isolates were collected at 8 US sites from 458 infants hospitalized for RSV disease (1998-2002). Palivizumab bound to all 371 RSV isolates able to be evaluated, including 25 from active-palivizumab recipients. The palivizumab epitope appears to be highly conserved, even in infants receiving prophylaxis with palivizumab.Entities:
Mesh：
Substances：
Year: 2004 PMID： 15295704 DOI： 10.1086/423213
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226